| Literature DB >> 27055875 |
C-H Tsai1,2,3, H-A Hou1, J-L Tang1,3, C-Y Liu4, C-C Lin1,2,5, W-C Chou1,5, M-H Tseng1, Y-C Chiang1, Y-Y Kuo6, M-C Liu7, C-W Liu7, L-I Lin8, W Tsay1, M Yao1, C-C Li1,3, S-Y Huang1, B-S Ko1, S-C Hsu5, C-Y Chen1, C-T Lin1,3, S-J Wu1, H-F Tien1.
Abstract
A number of patient-specific and leukemia-associated factors are related to the poor outcome in older patients with acute myeloid leukemia (AML). However, comprehensive studies regarding the impact of genetic alterations in this group of patients are limited. In this study, we compared relevant mutations in 21 genes between AML patients aged 60 years or older and those younger and exposed their prognostic implications. Compared with the younger patients, the elderly had significantly higher incidences of PTPN11, NPM1, RUNX1, ASXL1, TET2, DNMT3A and TP53 mutations but a lower frequency of WT1 mutations. The older patients more frequently harbored one or more adverse genetic alterations. Multivariate analysis showed that DNMT3A and TP53 mutations were independent poor prognostic factors among the elderly, while NPM1 mutation in the absence of FLT3/ITD was an independent favorable prognostic factor. Furthermore, the status of mutations could well stratify older patients with intermediate-risk cytogenetics into three risk groups. In conclusion, older AML patients showed distinct genetic alterations from the younger group. Integration of cytogenetics and molecular mutations can better risk-stratify older AML patients. Development of novel therapies is needed to improve the outcome of older patients with poor prognosis under current treatment modalities.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27055875 DOI： 10.1038/leu.2016.65
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528